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The recent availability for clinical use of a series of
recombinant human growth factors (HGFs) represents the
culmination of 25 years of intensive research into the
physiology of normal haemopoiesis. The development of
clonal assays for primitive murine haemopoietic cells in vivo
(Till and McCulloch, 1961) and then in vitro (Pluznick &
Sachs, 1965; Bradley & Metcalf, 1966) enabled the growth
requirements of developmentally early haemopoietic cells to
be studied. Progress was accelerated by the adoption of
successful strategies to clone the genes encoding for many of
the growth factors, referred to as colony-stimulating factors
by virtue of their ability to support the growth in vitro of
haemopoietic colonies (Metcalf et al., 1986; Clark & Kamen,
1987).
All myeloid and lymphoid cells arise from a common pool
of multipotential stem cells (Keller et al., 1985) which are
capable of self renewal or the formation of more mature
progeny. As the primitive cells proliferate there is
concomitant differentiation with increasing commitment to
one lineage, and then the acquisition of the mature
phenotype of a given cell lineage. Either the recruitment of
more primitive cells into the proliferating pool or the
insertion of extra cell divisions in the differentiation pathway
would result in amplification of the mature cell pool. These
processes of haemopoietic proliferation and differentiation
are controlled at least in part by the HGFs although, with
the exception of erythropoietin, the precise in vivo role of the
different factors is not understood.
The HGFs can be considered as three families of factors
with overlapping activities. Firstly, there are the late-acting
factors which are relatively lineage restricted and stimulate
the terminal divisions and differentiation of a specific cell
lineage (Table I). In addition, some of these factors have
profound functional effects upon the mature cells of that
lineage which are present in the peripheral blood. Secondly,
there are the multi CSFs, the paradigm example of which is
interleukin 3 (IL-3). The activity of this factor is largely
limited to cells at an intermediate stage of differentiation,
although the earlier cells of many haemopoietic lineages
express receptors and respond to this factor (Bot et al.,
1988). Granulocyte-macrophage colony-stimulating factor
(GM-CSF) does not fit readily into either of the above two
categories. It shares many of the multi-CSF activities with
IL-3, although probably acting on a slightly 'later' cell. In
addition, as its name implies it also stimulates the terminal
divisions of the granulocyte and monocyte series, and
modulates the function of mature granulocytes and
monocytes analogous to the other 'late acting factors' (Sieff
et al., 1985; Clark & Kamen, 1987).
Thirdly, there are the factors such as IL-1 (also called
haemopoietin 1) and IL-6 which affect very primitive
haemopoietic cells. These cells are difficult to study by virtue
of their rarity and their requirement for the marrow micro-
environment (Dexter et al., 1977) so that the precise effects
of IL-1 and IL-6 are not fully clear. It appears that these
factors render the most primitive cells sensitive to the 'multi
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CSFs' and later acting factors, by stimulating division and
maturation of these early cells, by upregulating the receptors
for the multi CSFs and later acting factors independent of
cell division, or by inducing the transition of primitive cells
from Go to G1 and thus rendering them more sensitive to
the effects of other factors. In vitro IL-1 alone does not
cause colony growth but combined with other factors it
permits the growth of very large colonies from primitive cells
(Stanley et al., 1986). For this reason, it is often referred to
as a synergistic factor. As one moves from the late-acting
factors to the early-acting factors there is increasing
promiscuity of target cell reactivity so that, whereas the
effects of G-CSF are largely restricted to cells of the
committed granulocyte lineage IL-1 and IL-6 have multiple
activities, including effects on lymphocytes and hepatocytes
and the induction of fever (Durum et al., 1985; Wong &
Clark, 1988). This has obvious implications for clinical
exploitation.
In vivo animal studies with the recombinant HGFs have
been in accord with the results of previous in vitro studies.
G-CSF causes a rapid rise in the neutrophil count in
hamsters with no change in the monocyte, eosinophil or
lymphocyte count (Cohen et al., 1987). Similar effects are
produced in cynomolgus monkeys except that there is also a
rise in the T lymphocyte numbers (Welte et al., 1987). The
circulating granulocytes are functionally 'primed' in vivo and
Table I Haemopoietic growth factors
Haemopoietic
growth factor
Erythropoietin
G-CSF
M-CSF
GM-CSF
IL-3
IL-1
IL-6
Molecular
weight (kD)' In vitro effects
34-39 Stimulates growth of erythroid
and megakaryocyte colonies
18-22 Stimulates growth of
granulocyte colonies, activation
of mature granulocytes
70-90 Stimulates weakly the growth
of monocyte colonies,
activation of mature monocytes
14-21 Stimulates growth of
granulocyte and monocyte
colonies, stimulates early
growth of erythroid and
megakaryocyte progenitor cells,
activation of mature
granulocytes and monocytes
14-28 Stimulates early growth of
granulocyte, monocyte,
erythroid and megakaryocyte
progenitor cells
15-20 Renders myeloid stem cells
sensitive to 'later' acting
factors, multiple effects on
lymphoid and other non-
haemopoietic cells
26 As for IL-I?
aVariation due to glycosylation, except for M-CSF, in which two
forms of the protein exist due to alternative splicing. The M-CSF
proteins are both homodimers.
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demonstrate enhanced phagocytosis and killing activity
(Welte et al., 1987). Human studies demonstrate a similar
rapid and marked rise in the neutrophil count with only a
minor rise in the monocyte and lymphocyte numbers and
with no change in the eosinophil or platelet counts
(Bronchud et al., 1987; Morstyn et al., 1988).
Intraperitoneal injections of recornbinant murine GM-
CSF into mice cause a moderate increase in circulating
neutrophils with accumulation of neutrophils, monocytes
and eosinophils in the peritoneal cavity (Metcalf et al.,
1987). This is associated with decreased cellularity and
decreased progenitor cell content of the marrow. In non-
human primates GM-CSF causes a marked rise in the
peripheral neutrophil and eosinophil count with a slightly
lesser rise in the monocyte and lymphocyte counts (Donahue
et al., 1987; Mayer et al., 1987). In contrast to murine
studies there is no decrease in bone marrow cellularity. The
initial human studies in patients with HIV infections showed
that GM-CSF caused a similarly rapid rise in circulating
neutrophil, eosinophil and monocyte numbers, associated
with increased bone marrow cellularity (Groopman et al.,
1987). The circulating phagocytes are also primed by GM-
CSF and show enhanced phagocytosis and killing ability
(Baldwin et al., 1988). Human GM-CSF has also been shown
to accelerate haemopoietic recovery in monkeys given total
body irradiation (Nienhuis et al., 1987). More rapid platelet
recovery, as well as neutrophil recovery, was noted.
Although accelerated neutrophil recovery and phagocyte
priming is likely to be beneficial with regard to infection
control, infusions of GM-CSF in -man have been shown
to inhibit neutrophil migration from zones of traumatised
skin (Addison et al., unpublished observations). It is possible
that high levels of GM-CSF might prevent infiltration of
foci of deep seated tissue infections, and careful dose ranging
studies are essential. Similar studies have not been reported
with G-CSF.
IL-3 given intraperitoneally to mice results in peripheral
blood eosinophilia, neutrophilia and monocytosis (Metcalf et
al., 1986). There is an expansion of the progenitor cell
compartment, which is located within the spleen rather than
the bone marrow. In primates IL-3 causes a modest but
delayed leukocytosis relative to the effects of G-CSF or
GM-CSF. Prior treatment with IL-3 augments the response
to GM-CSF, supporting the concept that IL-3 acts on an
immature cell population which can then be stimulated to
proliferate and terminally differentiate in response to a
second later acting factor (Donahue et al., 1987b).
IL-1 has been reported to hasten granulocyte recovery
following chemotherapy in mice, particularly when given in
combination with G-CSF (Stork et al., 1987; Moore &
Warren, 1987). In monkeys IL-1 had no effect on
granulocyte recovery but did appear to accelerate platelet
recovery (Monroy et al., 1987). Most interestingly, IL-1
given before sub-lethal total body irradiation has been
reported to prevent severe myelosuppression (Neta et al.,
1986). The mechanism is obscure. The in vivo effects of IL-1
are particularly difficult to evaluate because of its
multisystem effects, including the potent stimulation of the
production of other haemopoietic growth factors, in addition
to its direct effects on early stem cells.
There are numerous potential clinical uses for the HGFs
and some of these are listed in Table II. The HGFs might be
expected to minimise any period of chemo/radiotherapy-
induced cytopaenia and this is the situation in which they
have been largely tested. With relatively less intensive
therapy producing only several days of severe neutropaenia
G-CSF would seem on theoretical grounds to be the factor
of choice because of its restricted activity. With more
intensive therapy, which would further deplete primitive cell
pools, or in heavily pretreated patients, a factor active on
earlier cells, such as GM-CSF, might seem preferable. A
multi CSF might be expected also to accelerate red cell and,
more importantly, platelet recovery.
Table II Potential clinical uses of haemopoietic growth factors
1. To stimulate normal haemopoiesis
(a) following chemo/radiotherapy
(b) aplastic anaemia
(c) anaemia of chronic renal failure, anaemia of prematurity
and anaemia of chronic disease (erythropoietin)
(d) adjunct to autologous blood transfusion (erythropoietin)
2. Radioprotective effect (IL-1)
3. To enhance the harvesting of peripheral blood stem cells
4. To stimulate leukaemic cells
(a) to increase differentiation of leukaemic cells in
myelodysplasia
(b) to induce leukaemic stem cells into cycle before
chemotherapy
5. To stimulate mature phagocyte cell function
(a) infection
(b) neoplasia
6. To prolong life of harvested granulocytes for transfusion
Following intermediate dose therapy given for small cell
carcinoma of the lung (Bronchud et al., 1987), a variety of
metastatic cancers (Morstyn et al., 1988) and transitional cell
carcinoma of the uroepithelium (Gabrilove et al., 1988), G-
CSF caused a dose-dependent reduction in the neutrophil
nadir and the duration of neutropaenia. At the highest level
used there was also a more prompt recovery of the monocyte
count (Gabrilove et al., 1988). The incidence of
chemotherapy associated sepsis appeared to be less in
recipients of G-CSF (Bronchud et al., 1987; Gabrilove et al.,
1988) and in one study there was a significant reduction
in the incidence of mucositis (Gabrilove et al., 1988). The
only toxicity reported was mild to moderate bone pain asso-
ciated with the G-CSF infusions (Morstyn et al., 1988;
Gabrilove et al., 1988). These encouraging studies have been
carried out with chemotherapy protocols where the period
of severe neutropaenia (<0.5 x 1091 -) is relatively short,
and it will be of great interest to see whether G-CSF proves
as efficacious with more intensive therapy, particularly
in the heavily pretreated patient.
GM-CSF has also been reported to accelerate
haemopoietic recovery following myelosuppressive therapy.
In a study of eight patients receiving chemotherapy for
inoperable sarcomas, GM-CSF, when administered after
cessation of chemotherapy, resulted in higher nadir
neutrophil counts and fewer neutropaenic days when
compared to a cycle ofdrugs in which the GM-CSF was not
given (Antman et al., 1987). GM-CSF has also been
evaluated with very intensive therapy made possible by
autologous bone marrow rescue (Brandt et al., 1988;
Devereux et al., 1988b). In the study by Brandt and
colleagues, once the neutrophils began to appear in the
blood there was a rapid rise so that the neutrophil count at
day 15 was significantly higher than in the historical control
group. There was, however, only a slight shortening of the
time to achieve a neutrophil count of 0.5 x 1091-1, which is
conventionally taken to be a 'safe level'. In our own study in
patients receiving intensive chemotherapy and autologous
bone marrow transplants (ABMT) for resistant Hodgkin's
disease, the median time to achieve a neutrophil count of
0.5 x 1091-1 was, by contrast, reduced by 8 days. This
difference may reflect that regeneration from ABMT in
pretreated patients with Hodgkin's disease is slower than
that following ABMT for other solid tumours.
Disappointingly, in neither of these studies was there an
acceleration of the platelet recovery.
Several side effects of GM-CSF treatment have been
observed. Low grade fever and thrombophlebitis have been
noted in a number of studies (Groopman et al., 1987;
Devereux et al., 1987). Bone pain has been reported in some
patients, especially during bolus infusions (Vadhan-Raj et
al., 1987). At the highest doses (32-644ugkg-1day-1), more4 S. DEVEREUX & D.C. LINCH
severe toxicity has been observed with central venous
thrombosis and a capillary endothelial 'leak' syndrome
(Brandt et al., 1988). GM-CSF causes transient margination
of neutrophils with sequestration in the lungs, which appears
to be due in part to increased expression of adhesion
promoting glycoproteins (Devereux et al., 1986). Many of
the observed side effects of GM-CSF therapy could be
explained by the combination of abnormal adherence of
phagocytic cells to the vascular endothelium and of
activation of any circulating monocytes and tissue
macrophages.
Although autologous bone marrow transplantation
represents an excellent model for testing the effects of
GM-CSF, the indications for ABMT are few, and even if
the HGFs become widely used in this setting there will be
little impact in the overall field of oncology. With
conventional therapy, as currently used in the lymphomas
and solid tumours, there is probably little need for HGFs.
With chemotherapy that causes severe neutropaenia of only
several days duration the incidence of severe sepsis is
generally low and it will be very difficult to demonstrate an
improvement in therapy-related mortality. Perhaps the most
exciting potential application is the use of the HGFs to
allow doseage escalation, to enable high doses of drugs or
radiotherapy to be given over a shorter period of time. There
are data for several tumour types to suggest that the
optimum tumour responses are obtained when the highest
tolerated doses of drugs are given early in the treatment
protocol (De Vita, 1985), and the HGFs might enable more
efficacious treatment rather than just reduced toxicity. With
increasing intensity of therapy, thrombocytopaenia becomes
increasingly problematic and full exploitation of this
approach may await the development of 'thrombopoietin'.
Erythropoietin will support megakaryocyte colony growth in
vitro and it will be important to determine the effects of IL-3
and erythropoietin or GM-CSF and erythropoietin on
platelet recovery. It is likely that combinations of HGFs will
be more efficacious than single factors and the current
studies with single factors must be viewed as the first step on
a long journey. It is conceivable that HGFs would not only
enable shorter treatment courses but that this could also be
economically beneficial, with a shorter period of
hospitalisation and less use of antibiotics and blood
products. For widespread outpatient use this will probably
require subcutaneous or even 'depot-preparation'
administration. G-CSF can be given subcutaneously and
studies are also in progress with GM-CSF although with
any factor that stimulates macrophages there is the
theoretical risk of granuloma formation at the injection site.
The effects of G-CSF and GM-CSF in man have been
largely predictable from previous in vitro and in vivo animal
studies. None the less, these phase I/II studies have increased
our understanding of the normal physiology of haemopoiesis
and the inflammatory process. The clinical value of the
HGFs is still unproved, although the preliminary data are
encouraging.. Well-designed randomised trials are now
required to address the important biological issues and not
just to satisfy the demands of the licensing authorities.
Assessment of treatment efficacy must be based on
quantifiable clinical endpoints and not just changes in the
blood count.
References
ANTMAN, L.K., GRIFFIN, J., ELIAS, A. & 7 others (1987). Use of
rGM-CSF to ameliorate chemotherapy induced myelo-
suppression in sarcoma patients. Blood., 70, Suppl., 373.
BALDWIN, G.C., GASSON, J.C., QUAN, S.G. & 5 others (1988).
Granulocyte-macrophage colony-stimulating factor enhances
neutrophil function in acquired immunodeficiency syndrome
patients. Proc. Natl Acad. Sci. USA, 85, 2763.
BRADLEY, T.R. & METCALF, D. (1966). The growth of mouse bone
marrow cells in vitro. J. Cell. Comp. Physiol., 66, 287.
BOT, F.J., DORSSERS, L., WAGEMAKER, G. & LOWENBERG, B.
(1988). Stimulatory spectrum of human recombinant multi CSF
(IL-3). Blood, 71, 1609.
BRANDT, S.J., PETERS, W.P., ATWATER, S.K. & 7 others (1988).
Effect of recombinant human granulocyte-macrophage colony-
stimulating factor on haemopoietic reconstitution following high
dose chemotherapy and autologous bone marrow trans-
plantation. N. Engl. J. Med., 318, 869.
BRONCHUD, M.H., SCARFFE, J.H., THATCHER, N. & 5 others
(1987). Phase I/II study of recombinant human granulocyte
stimulating factor in patients receiving intensive chemotherapy
for small cell lung cancer. Br. J. Cancer, 56, 809.
CLARK, S.C. & KAMEN, R. (1987). The human haemotopoietic
colony stimulating factors. Science, 236, 1229.
COHEN, A.N., ZSEBO, K.B., INOUE, H. & 6 others (1987). In vivo
stimulation of granulopoiesis by recombinant human granulocyte
stimulating factor. Proc. Natl Acad. Sci. USA, 84, 2484.
DEVEREUX, S., LINCH, D.C., CAMPOS-COSTA, D., SPITTLE, M.F. &
JELLIFFE, A.M. (1987). Transient leucopenia induced by
granulocyte-macrophage colony-stimulating factor (letter).
Lancet, ii, 1523.
DEVEREUX, S., BULL, H.A., CAMPOS-COSTA, D., SAIB, R. & LINCH,
D.C. (1988a). Granulocyte macrophage colony stimulating factor
induced changes in cellular adhesion molecule expression and
adhesion to endothelium: In vitro and in vivo studies in man.
Br. J. Haematol. (in press).
DEVEREUX, S., LINCH, D.C., PATTERSON, K.P., GRIBBEN, J.G.,
McMILLAN, A. & GOLDSTONE, A.H.G., (1988b). GM-CSF
accelerates neutrophil recovery after autologous bone marrow
transplantation for Hodgkin's disease. Bone Marrow Transplan-
tation (in press).
DE VITA, V.T. (1985). Principles and Practice of Oncology, 2nd
edition, p. 266. Lippincott: Philadelphia.
DEXTER, T.M., ALLEN, T.D. & LAJTHA, L.G. (1977). Conditions
controlling the proliferation of haemopoietic stem cells in vitro.
J. Cell. Physiol., 91, 335.
DONAHUE, R.E., WANG, E.A., STONE, D.K. & 5 others (1987a).
Stimulation of haematopoiesis in primates by continuous
infusion of recombinant human GM-CSF. Nature, 321, 872.
DONAHUE, R.E., SEEHRA, J., ROTON, C. & 7 others (1987b).
Stimulation of haematopoiesis in primates with human
interleukin-3 and granulocyte macrophage colony stimulating
factor (abstr.). Blood, 70, Suppl. 1, 388.
DURUM, S.K., SCHMIDT, J.A. & OPPENHEIM, J.J.S. (1985).
Interleukin 1: An immunological perspective. Ann. Rev.
Immunol., 3, 263.
GABRILOVE, J.L., JAKUBOWSKI, A., SCHER, H. & 11 others (1988).
Effect of granulocyte colony stimulating factor on neutropaenia
and associated morbidity due to chemotherapy for transitional
cell carcinoma of the urothelium. N. Engl. J. Med., 318, 1414.
GROOPMAN, J.E., MITSUYASU, R.T., DELEO, M.J., DETTE, D.H. &
GOLDE, D.W. (1987). Effect of granulocyte-macrophage colony-
stimulating factor on myelopoiesis in the acquired immune
deficiency syndrome. N. Engl. J. Med., 317, 593.
KELLER, G., PAIGE, C., GILBOA, E. & WAGNER, E.F. (1985).
Conditions controlling the proliferation of haemopoietic stem
cells in vitro. J. Cell. Physiol., 91, 335.
MAYER, P., LAM, C., OBENAUS, H., LIEBL, E. & BESSENER, J.
(1987). Recombinant human GM-CSF induces leukocytosis and
activates peripheral blood polymorphonuclear neutrophils in non
human primates. Blood, 70, 206.
METCALF, D., BEGLEY, C.G., JOHNSON, G.R.M., NICOLA, N.A.,
LOPEZ, A.F. & WILLIAMSON, D.J. (1986). Effects of purified
bacterially synthesised murine multi CSF (IL-3) on
haematopoiesis in normal adult mice. Blood, 68, 46.
METCALF, D., BEGLEY, C.G., WILLIAMSON, D.J. & 5 others (1987).
Haemopoietic responses in mice injected with purified
recombinant murine GM-CSF. Exp. Haematol., 15, 1.
MONROY, R.L., SKELLY, R.R., DAVIS, T.A. & 5 others (1987). Effect
of interleukin-1 on the recovery of primates after radiation and
autologous bone marrow transplantation. Blood, 70, Suppl.,
1103.HAEMOPOIETIC GROWTH FACTORS 5
MOORE. M.A. & WARREN, D.J. (1987). Synergy of interleukin 1 and
granulocyte colony stimulating factor: In vivo stimulation of stem
cell recovery and haemopoietic regeneration following 5-
fluorouracil treatment of mice. Proc. Natl Acad. Sci. USA, 84,
7134.
MORSTYN, G., CAMPBELL, L., SOUZA, L.M. & 5 others (1988).
Effect of granulocyte colony stimulating factor on neutropaenia
induced by cytotoxic chemotherapy. Lancet, i, 667.
NETA, R., DOUCHES, S. & OPPENHEIM, J.J. (1986). Interleukin 1 is a
radioprotector. J. Immunol., 136, 2483.
NIENHUIS, A.W., DONAHUE, R.E., KARRISON, S. & 7 others (1987).
Recombinant human granulocyte-macrophage colony-stimulating
factor shortens the period of neutropaenia after autologous bone
marrow transplantation in a primate model. J. Clin. Invest., 80,
573.
PLUZNIK, D.H. & SACHS, L. (1965). The cloning of normal mast
cells in cell culture. J. Cell. Comp. Physiol., 66, 319.
SIEFF, C.A., EMERSON, S.G., DONAHUE, R.E. & 5 others (1985).
Human recombinant granulocyte-macrophage colony-stimulating
factor: A human multilineage hemopoietin. Science., 230, 1171.
STANLEY, E.R., BARTOCCI, A., PATINKIN, D., ROSENDAAL, M. &
BRADLEY, T.R. (1986). Regulation of very primitive, multipotent,
hemopoietic cells by hemopoietin 1. Cell, 45, 667.
STORK, L., KISSINGER, M. & ROBINSON, W. (1987). Interleukin-1
hastens murine granulocyte recovery following treatment with
cyclophosphamide (abstr.). Blood, 70, Suppl. 1, 808.
TILL, J.E. & McCULLOCH, E.A. (1961). A direct measurement of the
radiation sensitivity of normal mouse bone marrow cells.
Radiation Res., 14, 213.
VADHAN-RAJ, S., KEATING, M., LEMAISTSRE, A & 5 others (1987).
Effects of recombinant human granulocyte-macrophage colony-
stimulating factor in patients with myelodysplastic syndromes. N.
Engl. J. Med., 317, 1545.
WELTE, K., BONILLA, M.A., GILLIO, A.P. & 6 others (1987).
Recombinant human granulocyte colony stimulating factor (G-
CSF). J. Exp. Med., 165, 941.
WONG, G.C. & CLARK, S.C. (1988). Multiple actions of interleukin 6
within a cytokine network. Immunol. Today, 9, 137.